Cumberland Pharmaceuticals Inc
CPIX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001087294
No open-market purchases or sales by Cumberland Pharmaceuticals Inc insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $16.0M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Cumberland Pharmaceuticals Inc as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- −2 vs. Q2 2023
- Shares held
- 2.21M
- −191.5K (−8.0%) vs. Q2 2023
- Total value
- $4.17M
- +$645.9K (+18.3%) vs. Q2 2023
- New holders
- 2
- 2 more added
- Sold out
- 4
- 8 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CPIX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 32 | $16.0M |
| Q1 2026 | 29 | $8.97M |
| Q4 2025 | 27 | $11.8M |
| Q3 2025 | 30 | $10.6M |
| Q2 2025 | 31 | $12.3M |
| Q1 2025 | 33 | $18.1M |
| Q4 2024 | 20 | $4.36M |
| Q3 2024 | 22 | $2.61M |
| Q2 2024 | 23 | $3.18M |
| Q1 2024 | 23 | $3.63M |
| Q4 2023 | 25 | $3.89M |
| Q3 2023 | 21 | $4.17M |
| Q2 2023 | 23 | $3.52M |
| Q1 2023 | 21 | $4.77M |
| Q4 2022 | 23 | $5.61M |
| Q3 2022 | 17 | $5.89M |
| Q2 2022 | 22 | $5.62M |
| Q1 2022 | 26 | $8.17M |
| Q4 2021 | 26 | $13.2M |
| Q3 2021 | 23 | $7.43M |
| Q2 2021 | 28 | $8.36M |
| Q1 2021 | 31 | $9.77M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Cumberland Pharmaceuticals Inc; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Renaissance Technologies LLC | 555,763 | $1.05M | 0.00% | −4,980−0.9% | Reduced |
| Dimensional Fund Advisors LP | 379,720 | $717.7K | 0.00% | −127,570−25.1% | Reduced |
| Vanguard Group Inc | 373,126 | $705.2K | 0.00% | −1,700−0.5% | Reduced |
| Bridgeway Capital Management, LLC | 286,655 | $541.8K | 0.01% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 188,164 | $354.0K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 110,990 | $209.8K | 0.00% | −2,701−2.4% | Reduced |
| Geode Capital Management, LLC | 85,274 | $161.2K | 0.00% | +10,691+14.3% | Added |
| Bank of New York Mellon Corp | 75,268 | $142.3K | 0.00% | +75,268 | New |
| State Street Corp | 39,790 | $75.2K | 0.00% | −3,255−7.6% | Reduced |
| Two Sigma Investments, LP | 33,230 | $62.8K | 0.00% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 23,600 | $44.6K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 19,824 | $37.5K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 11,274 | $21.3K | 0.00% | 00.0% | Unchanged |
| Cresset Asset Management, LLC | 11,025 | $20.8K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 5,933 | $11.2K | 0.00% | −13,776−69.9% | Reduced |
| Tower Research Capital LLC (TRC) | 5,032 | $9.51K | 0.00% | −2,231−30.7% | Reduced |
| Oakworth Capital, Inc. | 3,052 | $5.77K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 61 | $115 | 0.00% | +2+3.4% | Added |
| JPMorgan Chase & Co | 10 | $19 | 0.00% | +10 | New |
| Huntington National Bank | 1 | $2 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 148 | $0 | 0.00% | −163−52.4% | Reduced |
| National Asset Management, Inc. | 0 | $0 | 0.00% | −90,298−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −11,715−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −10,436−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −8,616−100.0% | Sold out |